G20 summit today featured many pledges, promises and proposals to address global gaps in COVID19 vaccine access. We'll have to see how many of these become concrete actions in the weeks and months ahead. reuters.com/world/g20-heal…
Pfizer promised to provide 2 billion doses "at cost" for lower income countries over the next 18 months: 1 billion by the end of this year and another billion by the middle of 2022. reuters.com/business/healt…
.@gavi and J&J announced a purchase agreement of 200 million doses of the J&J vaccine for distribution through COVAX this year gavi.org/news/media-roo…
The EU said it will be investing 1 billion Euros to help build vaccine manufacturing hubs in Africa in.news.yahoo.com/news/eu-invest…
There was no agreement on patent waivers; in the statement from the G20 the members urged technology transfer and voluntary licensing to help boost global COVID-19 vaccine manufacturing.
And, no commitments from the G20 to fill the $19 billion financing gap for the WHO-led ACT Accelerator, designed to help distribute COVID-19 vaccines, drugs and tests to low and middle income countries.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Important data on "breakthrough" infections: CDC says 5,800 infections documented so far in the US, of which 396 (7%) needed to be hospitalized. About 77 million people have been fully vaccinated in the US. cnn.com/2021/04/14/hea…
CDC says a "little over 40% of the infections were in people 60 or more years of age" but hard to draw too many conclusions from that given that the preponderance of the vaccinated are in that age group, too.
We knew these infections would occur, and that some could lead to severe disease and even death. In this article alone, three different experts used the phrase "not surprising" to describe the phenomenon. Vaccines are not 100% protective. washingtonpost.com/health/2021/04…
In light of J&J news, of primary concern with regard to vaccine confidence in the US is the 15-20% of adults still on the fence about getting vaccinated. Could the pause, and the messaging around it, change minds from "wait and see" to "no thanks"? kff.org/coronavirus-co…
The most common concerns about vaccines in the "wait and see" group revolve around safety and side effects, so if a perception takes hold - for whatever reason - that a vaccine is "unsafe" it could have implications for willingness to be vaccinated especially in this group.
Can't predict how things will play out here, but concerning precedent that several European countries saw a decline in confidence in the AstraZeneca vaccine after a week-long pause initiated for similar reasons as we're seeing for J&J dw.com/en/european-tr…
30% of Israel's population has received at least 1 dose of Covid-19 vaccine, but no indications yet that case numbers are coming down there (chart).
A few reasons why this might be:
1) Cases reported now were infected 7+ days ago, when vaccinations were lower
2) Less than 500,000 (out of ~2.7 M vaccinated) have so far received a 2nd dose. A single dose is "less effective than we hoped" in providing protection, according to Israeli health leaders. theguardian.com/world/2021/jan…
3) Israel has vaccinated by age, starting with older persons, vaccinating to date:
80% of 70+
68% of 60-69
50% of 50-59
28% 40-49
Older ages are protected from severe disease, but younger ages typically contribute most to transmission timesofisrael.com/israelis-aged-…
Beyond the scientific and epidemiological reasons to doubt the lab escape theory of pandemic origin, let’s not forget that no US or allied intelligence has emerged with even a whiff of evidence that a lab was the origin by accident or intention.
To believe the lab escape theory you also have to believe the Chinese have mounted a successful, extended campaign to eliminate incriminating evidence and muzzle officials and scientists who knew or might have suspected it came from a lab.
It’s a pretty big secret to hold on to, especially for a sizeable group of people that includes an international network of scientists, other workers, and families -- many of whom are not exactly in the secrecy business.
That the US might adopt a 1 dose regimen or significantly delayed 2nd dose for vaccines already authorized seems more fanciful thought experiment than tractable policy. Pretty much all institutions and incentives are lined up against such a change and not without reason.
Current vaccines are authorized via EUAs from FDA, which both clearly state terms of use including a two-dose regimen. Moderna’s EUA says the vaccine is “administered as a series of two doses 1 month apart…”
“…Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.” modernatx.com/covid19vaccine…
2.17 million doses distributed through the federal pharmacy partnership prgm for long-term care, but only 167,149, or 7.8%, administered. This is the phase 1a component that needs to make up the most ground.
If this program were a state, it would easily be the worst performer.
States/jurisdictions' overall progress in administering the vaccines they have received continues to vary widely.
DC has administered over 50% of its vaccines on hand, while Kansas has administered just over 10%.